Arrowstreet Capital
CATX icon

Arrowstreet Capital’s Perspective Therapeutics CATX Stock Holding History

Arrowstreet Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,752
Closed -$117K – 1827
2024
Q4 		$117K Sell
36,752
-65,540
-64% -$535K ﹤0.01% 1680
2024
Q3 		$1.37M Buy
+102,292
New +$1.36M ﹤0.01% 1313

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arrowstreet Capital's CATX Position: Q1 2025 in Review

Arrowstreet Capital sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 36,752 shares — an estimated $117K sold.

Arrowstreet Capital first reported a position in CATX in Q3 2024 and held it in 2 quarters. The position peaked at $1.37M in Q3 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Arrowstreet Capital reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 36,752 Perspective Therapeutics shares in Q1 2025, an estimated $117K.
  • Arrowstreet Capital first reported a position in Perspective Therapeutics in Q3 2024 and held it in 2 quarters.
  • Arrowstreet Capital's Perspective Therapeutics position peaked at $1.37M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Arrowstreet Capital's 13F filing for Q1 2025, filed 14 May 2025.